echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Betta Pharmaceuticals' fourth new drug listing application was accepted and the third-generation EGFR-TKI was accepted

    Betta Pharmaceuticals' fourth new drug listing application was accepted and the third-generation EGFR-TKI was accepted

    • Last Update: 2021-03-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 3, Betta Pharmaceuticals announced that its third-generation EGFR-TKI befortinib mesylate capsule (BPI-D0316) has been accepted by the National Food and Drug Administration (NMPA) for the marketing authorization application, and it is intended for past use Treatment of locally advanced or metastatic non-small cell lung cancer with T790M mutation after EGFR-TKI resistance.


    EGFR is a group of cell surface receptors of the epidermal growth factor family with tyrosine kinase activity.


    Befortinib mesylate capsule is a third-generation EGFR-TKI developed by Betta Pharmaceuticals for the T790M mutation.


    The results of the study showed that the objective response rate (ORR) assessed by the Independent Review Committee (IRC) was 64.


    In terms of safety, the incidence of adverse reactions among subjects during the treatment period was 91.


    According to the press release, befortinib mesylate is a collaborative project developed by Betta Pharmaceuticals and Yifang Bio.


    Betta Pharmaceuticals focuses on the research and development of lung cancer targeted drugs.




    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.